Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o. — Clinical Trial Site

76 Registered trials

24 Currently recruiting

Organisation

Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.

Location

Nowa Sol, Poland

Identifier

ORG-100042644

Address

Ul. Glowackiego 8d/2, 67-100, Poland

Departments

-
#3208 - N/A
#40091; Neurology
#40091: nap
#40091: Neurology
#40091: Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o. o.
#413: Twoja Przychodnia Nowosolskie Centrum Medyczne
40091: Twoja Przychodnia Nowosolskie Centrum Medyczne
407_Twoja Przychodnia NCM
5213: Twoja Przychodnia NCM
Badania Kliniczne
Dermatology
N/A
NA
ND
Neurology
No Department
not applicable
Nowosolskie Centrum Medyczne
PL10010: Rheumatology
POL05434: Dermatology
reumathology
Twoja Przychodnia - Centrum Medyczne Nowa Sol
Twoja Przychodnia NCM
Twoja Przychodnia Nowosolskie Centrum Medyczne

Clinical trials at this site (76)

Search interface

A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder… Ended

2024-511549-20-00 Dermatitis atopic 4 2025-04-22
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN… Ended

2023-508812-45-00 Idiopathic Generalized Epilepsy with Generalized Tonic- 10 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr… Ended

2023-506185-31-00 Idiopathic pulmonary fibrosis (IPF) 10 2024-07-18
A Study to Evaluate the Safety and Effectiveness of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-510238-10-00 Moderate to Severe Atopic Dermatitis 4 2024-05-13
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub… Ended

2023-508013-16-00 Birch pollen induced allergic rhinitis or rhinoconjunct 5 2024-02-26
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended

2024-514764-72-00 Chronic Urticaria 5 2023-09-27
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended

2022-501425-20-00 Rheumatoid Arthritis Arthritis Joint Diseases Muscul 4 2023-04-03
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509783-23-00 Diffuse Cutaneous Systemic Sclerosis 4 2023-02-24
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Chronic Obstructive Pulmonary Disease (COPD) 4 2022-01-27
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509782-20-00 Diffuse Cutaneous Systemic Sclerosis 4 2021-11-11
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-04-06